March 2024
1. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
   Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
   Lancet. 2024;403:1061-1070.
   

   >> Share

   
   
2. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
   Ambulatory blood pressure monitoring and mortality - Authors' reply.
   Lancet. 2024;403:812.
   

   >> Share

   
   
3. LIU W, Ge W, Fan X, Du Y, et al
   Ambulatory blood pressure monitoring and mortality.
   Lancet. 2024;403:811-812.
   

   >> Share

   
   
4. MARTINEZ-GARCIA MA, Pengo MF, Parati G
   Ambulatory blood pressure monitoring and mortality.
   Lancet. 2024;403:810-811.
   

   >> Share

   
   
5. CHU WM, Ho HE, Wei JC
   Ambulatory blood pressure monitoring and mortality.
   Lancet. 2024;403:810.
   

   >> Share

   
   
6. LI SQ, Zhou JP, Wang Y, Li QY, et al
   Ambulatory blood pressure monitoring and mortality.
   Lancet. 2024;403:809-810.
   

   >> Share

   
   November 2023
7. JACKSON R, Rodgers A
   The ESH guidelines and missed prevention opportunities.
   Lancet. 2023;402:1729-1730.
   

   >> Share

   
   October 2023
8. MESSERLI FH, Bangalore S, Mandrola JM
   beta blockers switched to first-line therapy in hypertension.
   Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
   

   >> Share

   
   
9. KIVUYO S, Birungi J, Okebe J, Wang D, et al
   Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
   Lancet. 2023;402:1241-1250.
   

   >> Share

   
   
10. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    

    >> Share

    
    June 2023
11. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    

    >> Share

    
    
12. MANCIA G
    Evidence in favour of ambulatory blood pressure grows but gaps in knowledge remain.
    Lancet. 2023;401:2014-2015.
    

    >> Share

    
    
13. STAPLIN N, de la Sierra A, Ruilope LM, Emberson JR, et al
    Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.
    Lancet. 2023;401:2041-2050.
    

    >> Share

    
    
14. PLATZBECKER U, Della Porta MG, Santini V, Zeidan AM, et al
    Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Lancet. 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874.
    

    >> Share

    
    April 2023
15. DIXON SB, Liu Q, Chow EJ, Oeffinger KC, et al
    Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.
    Lancet. 2023;401:1447-1457.
    

    >> Share

    
    
16. BHATT DL, Bakris GL
    Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply.
    Lancet. 2023;401:1337-1338.
    

    >> Share

    
    
17. TANEMOTO M
    Key questions regarding the SYMPLICITY HTN-3 trial.
    Lancet. 2023;401:1337.
    

    >> Share

    
    
18. KJELDSEN SE, Burnier M, Narkiewicz K, Kreutz R, et al
    Key questions regarding the SYMPLICITY HTN-3 trial.
    Lancet. 2023;401:1336-1337.
    

    >> Share

    
    March 2023
19. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    

    >> Share

    
    December 2022
20. KRAMER CK, Leitao CB, Viana LV
    The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.
    Lancet. 2022;400:2074-2083.
    

    >> Share

    
    November 2022
21. WEATHERALD J, Boucly A, Peters A, Montani D, et al
    The evolving landscape of pulmonary arterial hypertension clinical trials.
    Lancet. 2022;400:1884-1898.
    

    >> Share

    
    
22. SCHLAICH MP, Bellet M, Weber MA, Danaietash P, et al
    Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02034.
    

    >> Share

    
    
23. DECHEND R, Delles C
    Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02181.
    

    >> Share

    
    October 2022
24. FANELLI E, Persu A
    SYMPLICITY HTN-3: failure at 6 months, success at 3 years?
    Lancet. 2022;400:1382-1383.
    

    >> Share

    
    
25. SALAH HM, Mehta JL
    Best time for administration of antihypertensive medications: morning or evening?
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01900.
    

    >> Share

    
    
26. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
    

    >> Share

    
    September 2022
27. BHATT DL, Vaduganathan M, Kandzari DE, Leon MB, et al
    Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Lancet. 2022 Sep 16. pii: S0140-6736(22)01787.
    

    >> Share

    
    
28. CLAASSEN J, Park S
    Spontaneous subarachnoid haemorrhage.
    Lancet. 2022;400:846-862.
    

    >> Share

    
    May 2022
29. SUN Y, Mu J, Wang DW, Ouyang N, et al
    A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.
    Lancet. 2022;399:1964-1975.
    

    >> Share

    
    April 2022
30. FIZAZI K, Foulon S, Carles J, Roubaud G, et al
    Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design.
    Lancet. 2022;399:1695-1707.
    

    >> Share

    
    
31. JAFAR TH, Jabbour S
    Village doctors managing hypertension in rural China.
    Lancet. 2022 Apr 29. pii: S0140-6736(22)00424.
    

    >> Share

    
    
32. MAHFOUD F, Kandzari DE, Kario K, Townsend RR, et al
    Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Lancet. 2022;399:1401-1410.
    

    >> Share

    
    
33. SARATHY H, Salman LA
    Can renal denervation replace medications for patients with hypertension?
    Lancet. 2022;399:1363-1365.
    

    >> Share

    
    
34. WALD NJ, Law M, Morris J, Wald DS, et al
    Blood pressure meta-analysis highlights an implementation gap.
    Lancet. 2022;399:1379-1380.
    

    >> Share

    
    November 2021
35. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.
    

    >> Share

    
    
36. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    

    >> Share

    
    
37. GARRISON SR, McCormack J
    Blood pressure treatment: how low should you go?
    Lancet. 2021;398:1684.
    

    >> Share

    
    September 2021
38. PEARLMAN B, Lodebo BT
    Renin secreting tumour: a rare cause of secondary hypertension.
    Lancet. 2021;398:1074.
    

    >> Share

    
    
39. KAHAN T
    Low-dose combination of blood pressure-lowering medicines.
    Lancet. 2021;398:1022-1023.
    

    >> Share

    
    
40. NGUYEN TN, Chow CK
    Global and national high blood pressure burden and control.
    Lancet. 2021;398:932-933.
    

    >> Share

    
    
41. JAFFAR S, Ramaiya K, Karekezi C, Sewankambo N, et al
    Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes.
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01731.
    

    >> Share

    
    August 2021
42. CHOW CK, Atkins ER, Hillis GS, Nelson MR, et al
    Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01922.
    

    >> Share

    
    
43. JACKSON R, Wells S
    Time to remove hypertension from our vocabulary?
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01916.
    

    >> Share

    
    
44. 
    Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    

    >> Share

    
    
45. 
    Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
    Lancet. 2021 Aug 24. pii: S0140-6736(21)01330.
    

    >> Share

    
    July 2021
46. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    

    >> Share

    
    
47. EL-QATRAWI KJ
    Effect of hypertension on pregnancy outcomes at UNRWA health centres in Gaza governorates: a comparative study.
    Lancet. 2021;398 Suppl 1:S26.
    

    >> Share

    
    May 2021
48. BROUWERS S, Sudano I, Kokubo Y, Sulaica EM, et al
    Arterial hypertension.
    Lancet. 2021 May 18. pii: S0140-6736(21)00221.
    

    >> Share

    
    
49. AZIZI M, Sanghvi K, Saxena M, Gosse P, et al
    Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)00788.
    

    >> Share

    
    
50. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.
    

    >> Share

    
    
51. 
    Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    

    >> Share

    
    March 2021
52. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share